Chu Brest
Brest, France
NCT Number: NCT04843605
COPD is a very common disease, an estimated 3 million people are affected in France. Unfortunately, this pathology is under-diagnosed. Several reasons can be mentioned: the banality of the symptoms or the several comorbidities.
Screening faces a major difficulty: the realization of a spirometry. Various studies have shown the complexity of the implementation of mass screening in cities by mini-spirometry.
The COPD World Health Days allow this mass screening but without visibility on the actual entry into a care pathway.
The objective of this study is to assess the impact of systematic screening for COPD during a tabacology consultation
Looking for future studies?
Notify Me45 year and older
All sexes
Observational
Brest, France
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: day 1
The diagnosis of COPD is performed using a spirometry
University Hospital, Brest
Other
Impact of Systematic Screening for COPD in Tabacology Consultation
Acronym: DEBOTA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05130788
Behavior, Health Behavior
New York, United States
View Trial DetailsNCT06663020
Behavior, Bronchial Neoplasms
Samsun, Turkey (Türkiye)
View Trial DetailsNCT04881630
Behavior, Health Behavior
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT04620915
Behavior, Cancer
Eugene, Oregon, United States
View Trial Details